IL6 and rheumatoid arthritis: In particular, the A2AAR agonist mediated a significant inhibition of IL-1β and IL-6 in ERA (62% and 66%, respectively), in RA (64% and 67%, respectively), in AS (62% and 67%, respectively) or in PsA patients (63% and 68%, respectively) (Figure 5A,B).